INS and type 2 diabetes mellitus: In STEP 2, semaglutide 2.4 mg led to 9.6% mean weight loss in people with T2D, as expected, slightly less than in non-diabetic populations; HbA1c reductions of ~ 1.6% and improved insulin sensitivity were observed [29].